All In Biotech

Drug Trial Radar · NCT06810505

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 420 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

420

Planned (sponsor's estimate)

Start

Feb 13, 2025

Primary completion

Mar 2031

Study completion Mar 2031

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Feb 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Migraine is a disease that most often causes moderate to severe headache on one side of the head. A migraine attack is a headache that may be accompanied by throbbing, nausea, vomiting, sensitivity to light and sound, or other symptoms. The goals of the study are to evaluate adverse events and how well treatment of atogepant works compared to placebo (looks like the study treatment but contains no medicine) in preventing chronic migraine in participants between 12 and 17 years of age. Atogepant is a medicine currently approved in the United States and Europe for the preventive treatment of migraine in adult patients with migraine and is being studied for the preventative treatment of chronic migraine in participants between the ages of 12 and 17 years. Participants will be randomly assigned to one of the 2 groups to be treated with either atogepant or placebo. This study is double-blinded, which means that neither the patients nor the study doctors know who is given which study treatment. Approximately 420 participants 12 to 17 years of age with chronic migraine will be enrolled at approximately 70 sites across the world. Participants will receive oral tablets of atogepant or placebo once daily for 12 weeks and will be followed for 4 weeks. Participants will attend regular visits during the study at a hospital or clinic and the effects of treatment will be checked by completion of a daily diary, medical assessments, blood tests, checking for side effects, and completing questionnaires.

Conditions

  • Chronic Migraine

Interventions

  • AtogepantDrug

    Oral tablet

  • Placebo for AtogepantDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse Events (AEs)Time frame: Up to approximately 16 weeks
  2. Change From Baseline in Mean Monthly Migraine DaysTime frame: Baseline (Week 0) through Week 12

Locations

66 sites in 11 countries. Site status is shown where the registry gives one.

  • Rehabilitation and Neurological Services /ID# 270782

    Huntsville, Alabama · Recruiting

  • Preferred Research Partners - Fayetteville /ID# 270419

    Fayetteville, Arkansas · Completed

  • Preferred Research Partners /ID# 270389

    Little Rock, Arkansas · Recruiting

  • Advanced Research Center /ID# 270257

    Anaheim, California · Recruiting

  • Neuro Pain Research Center /ID# 271048

    Fresno, California · Recruiting

  • Alliance for Research Alliance for Wellness /ID# 270398

    Long Beach, California · Recruiting

  • Excell Research /ID# 270258

    Oceanside, California · Recruiting

  • Lumos Clinical Research Center /ID# 270582

    San Jose, California · Recruiting

  • Sunwise Clinical Research /ID# 270431

    Walnut Creek, California · Recruiting

  • Northwest Florida Clinical Research Group, LLC /ID# 270833

    Gulf Breeze, Florida · Recruiting

  • Auzmer Research /ID# 271158

    Lakeland, Florida · Completed

  • My Preferred Research /ID# 270312

    Miami, Florida · Recruiting

  • Encore Medical Research - Weston /ID# 271139

    Weston, Florida · Recruiting

  • Pediatric Neurology & Epilepsy Center Of Central Florida - Winter Park /ID# 275263

    Winter Park, Florida · Recruiting

  • Deaconess Midtown Hospital /ID# 270572

    Evansville, Indiana · Recruiting

  • Michigan Headache & Neurological Institute /ID# 270942

    Ann Arbor, Michigan · Recruiting

  • Proven Endpoints LLC /ID# 270269

    Ridgeland, Mississippi · Recruiting

  • Cct Research - Papillion Research Center /ID# 270393

    Papillion, Nebraska · Recruiting

  • Healthy Perspectives - Innovate Mental Health Services /ID# 270847

    Nashua, New Hampshire · Recruiting

  • Dent Neurologic Institute - Amherst /ID# 270260

    Amherst, New York · Recruiting

  • Headache Wellness Center /ID# 270568

    Greensboro, North Carolina · Completed

  • The Children's Hospital of Philadelphia /ID# 270842

    Philadelphia, Pennsylvania · Recruiting

  • Frontier Clinical Research - Scottdale /ID# 270854

    Scottdale, Pennsylvania · Recruiting

  • Frontier Clinical Research - Smithfield /ID# 270849

    Smithfield, Pennsylvania · Recruiting

  • Access Clinical Trials Inc /ID# 270280

    Nashville, Tennessee · Recruiting

  • UT Health Austin at Dell Childrens Neurology Clinic /ID# 270577

    Austin, Texas · Recruiting

  • Earle Research /ID# 270424

    Houston, Texas · Recruiting

  • Clinpoint Trials /ID# 270261

    Waxahachie, Texas · Recruiting

  • Pantheon Clinical Research /ID# 270259

    Bountiful, Utah · Recruiting

  • Alpine Research Organization - Clinton /ID# 276527

    Clinton, Utah · Recruiting

  • Highland Clinical Research /ID# 270281

    Salt Lake City, Utah · Recruiting

  • Frontier Clinical Research - Kingwood /ID# 271053

    Kingwood, West Virginia · Recruiting

  • London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270659

    London, Ontario, Canada · Recruiting

  • McGill University Health Centre - Glen Site /ID# 270662

    Montreal, Quebec, Canada · Completed

  • Herlev Hospital /ID# 270482

    Herlev, Capital Region, Denmark · Recruiting

  • Regionshospitalet Godstrup /ID# 270481

    Herning, Central Jutland, Denmark · Recruiting

  • Semmelweis Egyetem /ID# 271219

    Budapest, Hungary · Recruiting

  • Rozsavolgyi Rendelo-Ceba Bt. /ID# 271500

    Budapest, Hungary · Recruiting

  • Fondazione IRCCS Istituto Neurologico Carlo Besta /ID# 270756

    Milan, Milano, Italy · Recruiting

  • Ospedale Pediatrico Bambino Gesu /ID# 270759

    Rome, Roma, Italy · Recruiting

Showing 40 of 66 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.